EMA reviewing use of Moderna jab in 12-17 y/os

Tuesday, 08. June 2021 16:28

The European Medicines Agency (EMA) announced on Tuesday it has started evaluating the use of Moderna Inc.'s vaccine against COVID-19 in young people aged between 12 and 17.

"EMA's human medicines committee (CHMP) will carry out an accelerated assessment of data submitted in the application, including results from a large ongoing clinical study involving adolescents from 12 to 17 years of age," the agency stated. "EMA will communicate the outcome of its evaluation, which is expected in July unless supplementary information is needed."

Moderna filed for the EMA's approval of the use of its jab in 12-to-17-year-olds earlier this week. The agency approved giving its vaccine to those older than 18 in January.

Related Links: 
Author:
Breaking the News / JR